Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

Original Article

S. Ständer, G. Yosipovitch, F.J. Legat, J.-P. Lacour, C. Paul, J. Narbutt, T. Bieber, L. Misery, A. Wollenberg, A. Reich, F. Ahmad, and C. Piketty

N Engl J Med 2020;382:706-716

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
02/19/2020
Course expires: 
02/20/2022

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Course closed

This course closed on Sunday, February 20, 2022 - 11:59pm.